Upper Gastrointestinal Cancers (UGCs) are a leading cause of cancer-related deaths worldwide. Paclitaxel (PTX) is frequently used for the treatment of UGCs; however, low bioavailability, reduced solubility, and dose-dependent toxicity impede its therapeutic use. PAMAMG -NH -DHA is synthesized by linking amine-terminated fourth-generation poly(amidoamine) (PAMAMG -NH ) dendrimers with omega-3 fatty acid docosahexaenoic acid (DHA). Next, PAMAMG -NH -DHA-PTX (DHATX) and PAMAMG -NH -PTX (PAX) conjugates are synthesized by subsequent covalent binding of PTX with PAMAMG -NH -DHA and PAMAMG -NH , respectively. H-NMR and MALDI-TOF analyses are performed to confirm conjugation of DHA to PAMAMG -NH and PTX to PAMAMG -NH -DHA. The cell viability, clonogenic cell survival, and flow cytometry analyses are used to determine the anticancer activity of PTX, PAX, and DHATX in UGC cell lines. The in vitro data indicate that treatment with DHATX is significantly more potent than PTX or PAX at inhibiting cellular proliferation, suppressing long-term survival, and inducing cell death in UGC cells.
Background: Paclitaxel (PTX) is frequently used for the treatment of advanced gastrointestinal (GI) cancers. However, development of drug resistance, dose-dependent toxicity, and lack of oral bioavailability are some of the major limiting factors that impede the therapeutic use of PTX for treatment of GI cancers. Drug conjugates of dendrimers, such as poly (amidoamine) (PAMAM), have been reported to effectively overcome bioavailability and dose-dependent toxicity related limitations. Therefore, in this study we synthesized and investigated the anticancer potential of omega-3 fatty acid [docosahexanoic acid (DHA)]-poly (amido)amine (PAMAM)-paclitaxel conjugates in various in vitro models of gastrointestinal cancers. Methods: DHA was conjugated to amine-terminated PAMAMG4 dendrimers using coupling agents HOBt and HBTU. PAMAMG4-DHA was then conjugated to PTX using PTX-NHS-ester. The conjugates were purified by size exclusion chromatography and characterized using 1H-NMR, MALDI-TOF-MS and high-resolution ESI-MS. The percentage payload of PTX conjugated to PAMAMG4-DHA and in vitro stability of PAMAMG4-DHA-PTX were evaluated using HPLC. Cell viability, clonogenic cell survival, and western blot analyses were done to evaluate the cell viability, survival, and induction of apoptotic proteins (P53 and P21), respectively. The in vitro cytotoxicity and induction of apoptosis was investigated in AGS, FLO-1, and MIA PaCa-2 GI cancer cell lines after treatment with PTX or PAMAMG4-DHA-PTX. Results: The 1H-NMR, MALDI-TOF and high-resolution ESI mass spectra confirmed the conjugation of DHA to PAMAM and PTX to PAMAM-DHA. The in vitro stability data showed that PAMAM-DHA-PTX conjugate was stable in human plasma for 24 hours. The cell viability data indicated that treatment with PAMAMG4-DHA-PTX is significantly more potent than PTX at inhibiting proliferation of esophageal (FLO-1: PTX IC50: 3.8±0.68 nM, PAMAMG4-DHA-PTX IC50: 1.1±0.17 nM), gastric (AGS: PTX IC50: 5.1±0.58 nM, PAMAMG4-DHA-PTX IC50: 1.4±0.23 nM), and pancreatic (MIA PaCa: PTX IC50: 5.1±0.75 nM, PAMAMG4-DHA-PTX IC50: 1.8±0.35 nM) cancer cell lines. The clonogenic cell survival data shows a similar activity where treatment with PAMAMG4-DHA-PTX exhibited enhanced inhibition of long term survival of FLO-1, AGS, and MIA PaCa cells when compared to PTX. The protein expression data further showed that compared to PTX treatment with PAMAMG4-DHA-PTX induced higher expression of P53 and P21 pro-apoptotic protein in AGS gastric cancer cell line. Conclusions: Overall our findings indicate that paclitaxel was successfully conjugated with PAMAMG4-DHA resulting in the synthesis of a novel PAMAMG4-DHA-PTX conjugate that exhibits enhanced anticancer activity than PTX alone in various in vitro models of GI cancers. Citation Format: Tanmay Dichwalkar, Samhita Bapat, Priya Pancholi, V. K. Yellepeddi, Vikas Sehdev. Omega-3 fatty acid conjugated paclitaxel dendrimers exhibit enhanced anticancer activity in various preclinical models of gastrointestinal cancers. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2200.
Central vasomotor effects of (−)-N-(1-phenylethyl)guanidine, a potent adrenergic neuron blocking agent, were studied. The compound was localized in the central sites by intracerebroventricular injection, topical application on the vasomotor center, intra-arterial (vertebral) injection, and intrathecal injection. It potentiated the carotid occlusion response, response to anoxia, spinal compression vasomotor response, and the threshold and optimal vasomotor responses to direct electrical stimulation of the medullary vasomotor center without affecting the peripheral norepinephrine pressor response and the nictitating membrane response. The peak effect was obtained in 15–20 min, and recovery occurred in 80–90 min. The compound probably made catecholamines unavailable to the vasomotor neurons, making them more excitable.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.